DGIdb - DEFERASIROX Drug Record

DEFERASIROX chembl:CHEMBL550348 Approved

Alternate Names:

DEFERASIROX
JADENU SPRINKLE
JADENU
EXJADE
ICL670
ICL-670
ICL670A
ICL-670A
ICL 670
ICL 670A
DEFERASIROXUM
drugbank:01609
rxcui:614373
pubchem.compound:5493381
chemidplus:201530-41-8
chembl:CHEMBL550348

Drug Info:

Drug Categories	benzoates
Drug Categories	compounds used in a research, industrial, or household setting
Drug Categories	cytochrome p-450 cyp1a2 inhibitors
Drug Categories	cytochrome p-450 cyp1a2 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	heavy metal antagonists
Drug Categories	iron chelating activity
Drug Categories	triazoles
Drug Categories	ugt1a1 inhibitors
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a3 inhibitors
Drug Categories	ugt1a9 inhibitors

(0 More Sources)

Publications:

Allegra S et al., 2019, The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients., Pharmacogenomics J
Cusato J et al., 2015, Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness., Pharmacogenomics J
Marano M et al., 2016, Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis., Eur J Clin Pharmacol
Allegra S et al., 2016, Deferasirox AUC efficacy cutoff and role of pharmacogenetics., Eur J Clin Pharmacol
Allegra S et al., 2018, Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes., Pharmacogenomics J
Allegra S et al., 2018, Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children., Pharmacogenet Genomics
Allegra S et al., 2017, Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients., Pharmacogenomics
Cusato J et al., 2016, Role of pharmacogenetics on deferasirox AUC and efficacy., Pharmacogenomics

DEFERASIROX CYP24A1

Interaction Score: 3.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29160302 29099735

Sources:
PharmGKB
DEFERASIROX CYP27B1

Interaction Score: 2.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30651574

Sources:
PharmGKB
DEFERASIROX UGT1A3

Interaction Score: 2.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28346059 27193993 27043265 30651574

Sources:
PharmGKB
DEFERASIROX GC

Interaction Score: 1.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30651574

Sources:
PharmGKB
DEFERASIROX CYP1A1

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25348619 27193993

Sources:
PharmGKB
DEFERASIROX ABCG2

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28346059 27193993 27043265

Sources:
PharmGKB
DEFERASIROX ABCC2

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25348619 26403473

Sources:
PharmGKB
DEFERASIROX CYP1A2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25348619 27193993

Sources:
PharmGKB
DEFERASIROX VDR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30651574

Sources:
PharmGKB
DEFERASIROX AR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB01609

Version: 5.1.7

Alternate Names:

DEFERASIROX DrugBank Drug Name

201530-41-8 CAS Number

Apo-deferasirox Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Devanur et al., 2008, Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy., Biochem. J.

Lebitasy et al., 2010, Ability of deferasirox to bind iron during measurement of iron., Clin. Chem. Lab. Med.

Yang et al., 2007, Deferasirox : a review of its use in the management of transfusional chronic iron overload., Drugs

PharmGKB: deferasirox

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Cusato J et al., 2015, Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness., Pharmacogenomics J

Marano M et al., 2016, Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis., Eur J Clin Pharmacol

Allegra S et al., 2019, The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients., Pharmacogenomics J

DTC: DEFERASIROX
- Version: 02-September-2020
Alternate Names:

CHEMBL550348 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL550348
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

DEFERASIROX	DrugBank Drug Name
201530-41-8	CAS Number
Apo-deferasirox	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

DEFERASIROX Drug Record

DEFERASIROX chembl:CHEMBL550348 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29160302 29099735

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30651574

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28346059 27193993 27043265 30651574

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30651574

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25348619 27193993

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28346059 27193993 27043265

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25348619 26403473

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25348619 27193993

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30651574

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

DrugBank: DB01609

Alternate Names: DEFERASIROX DrugBank Drug Name 201530-41-8 CAS Number Apo-deferasirox Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

PharmGKB: deferasirox

Alternate Names:

Drug Info:

DTC: DEFERASIROX

Alternate Names: CHEMBL550348 ChEMBL Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL550348

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
29160302 29099735

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30651574

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28346059 27193993 27043265 30651574

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30651574

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25348619 27193993

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28346059 27193993 27043265

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25348619 26403473

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25348619 27193993

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30651574

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

DEFERASIROX DrugBank Drug Name

201530-41-8 CAS Number

Apo-deferasirox Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

CHEMBL550348 ChEMBL Drug ID